Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Aravive Receives $6M Development Milestone From 3D Medicines

Aravive Inc. (NASDAQ:ARAV), a late clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, today announced that it received a $6 million development milestone
byBill Haddad
October 10, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Aravive Inc. (NASDAQ:ARAV), a late clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, today announced that it received a $6 million development milestone payment from its licensee, 3D Medicines Inc. This milestone is based on the initiation of the global Phase 3 platinum resistant ovarian cancer (PROC) clinical trial in China for the development of Aravive’s batiraxcept.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Sector Shifts: Bank of America Analyst Forecasts Challenging 2024 for Machinery, Downgrades Cummins and GFL, Upgrades PACCAR

By Lekha Gupta
January 19, 3:21 PM
BofA Securities' Michael Feniger adjusts ratings for machinery and energy companies, anticipating challenges in the machinery sector due to slow backlogs and moderating pricing. The analyst downgrades GFL Environmental and Cummins but upgrades PACCAR, reflecting a nuanced outlook amid expectations of a tightening cycle and global economic shifts.

CMI